|
|
Volumn 1, Issue 2, 2005, Pages 74-75
|
|
How does alemtuzumab affect long-term graft and patient outcomes after deceased-donor kidney transplantation?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALEMTUZUMAB;
CANCER ANTIBODY;
IMMUNOSUPPRESSIVE AGENT;
MONOCLONAL ANTIBODY;
ARTICLE;
CADAVER;
GRAFT SURVIVAL;
HUMAN;
KIDNEY TRANSPLANTATION;
TIME;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, NEOPLASM;
CADAVER;
GRAFT SURVIVAL;
HUMANS;
IMMUNOSUPPRESSIVE AGENTS;
KIDNEY TRANSPLANTATION;
TIME FACTORS;
|
|
EID: 33750945467
PISSN: 17458323
EISSN: None
Source Type: Journal
DOI: 10.1038/ncpneph0052 Document Type: Article |
|
Times cited : (1)
|
|
References (0)
|
